#GLP-1 class
Coverage of the GLP-1 receptor agonist family and its successors.
How GLP-1 Analogs Are Engineered
A 2026 review explains how GLP-1 analogs use sequence changes, peptide shape and lipidation to resist breakdown and last longer.
Incretins and MASLD: What 24 Trials Found
A 2026 review found better liver enzymes and MASH resolution with incretin therapies, but fibrosis regression remained uncertain.
Knee Surgery: Semaglutide vs Tirzepatide
A matched US study found similar short-term knee-replacement outcomes in people with diabetes prescribed semaglutide or tirzepatide.
Semaglutide pregnancy case series
A 2026 case series reported outcomes after first-trimester semaglutide exposure in 16 pregnancies. The result is useful but cannot establish safety.
Semaglutide in type 1 diabetes: ADJUST-T1D
ADJUST-T1D found better glucose-and-weight outcomes with semaglutide in selected adults, but it did not test long-term cardiovascular benefit.
Tirzepatide anhedonia: three case reports
Three patients reported improved motivation after tirzepatide dose reduction, but the uncontrolled case series cannot establish frequency or causation.
GLP-1 drugs in dermatologic disease
A 2026 review links GLP-1 drugs with inflammatory skin disease, but its clearest clinical evidence comes from one psoriatic arthritis trial.
GLP-1 drugs and diabetic foot reports
A 2026 FAERS analysis found a lower proportional reporting signal for diabetic foot complications, but it did not measure patient incidence or prove protection.
MASH fibrosis treatment panel update
An expert panel maps how semaglutide and resmetirom may fit MASH care, while long-term outcomes and direct comparisons remain open.
Semaglutide plus exercise in rats
A four-week rat study found partly distinct metabolic effects from semaglutide and aerobic training, with no direct evidence for menopausal women.
Semaglutide neuropathy case report
A single case found improved corneal nerve measurements after semaglutide, while neuropathy symptoms and disability scores stayed unchanged.
Semaglutide carbon model: what it found
A UK model estimated slightly lower lifetime emissions in two obesity populations but higher emissions with established cardiovascular disease.